December 5, 2016 / 6:12 PM / 9 months ago

BRIEF-Alnylam presents updated results from phase 1/2 study of ALN-CC5 in patients with paroxysmal nocturnal hemoglobinuria

Dec 5 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam presents updated results from phase 1/2 study of aln-cc5 in patients with paroxysmal nocturnal hemoglobinuria (pnh)

* Says new results show aln-cc5-mediated knockdown of serum c5 has potential to enable effective sparing of eculizumab in patients with pnh

* Says data support development of aln-cc5 to potentially reduce dose level and frequency of eculizumab in patients with pnh

* Says data further support development of aln-cc5 to improve disease control in patients with an inadequate response to eculizumab

* Says Sanofi Genzyme has decided not to exercise its opt-in right for development of aln-cc5 in territories outside of U.S., Canada, Western Europe

* Says Alnylam will have full global control of development of aln-cc5 program for further development and potential commercialization Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below